Study identifier:D6876C00023
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in patients with Early Prostate Cancer.
Non-metastatic prostate cancer
Phase 3
No
Bicalutamide, Placebo
Male
3618
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.
Location
Location
CALGARY, AB, Canada
Location
EDMONTON, AB, Canada
Location
HALIFAX, NS, Canada
Location
HAMILTON, ON, Canada
Location
KINGSTON, ON, Canada
Location
LONDON, ON, Canada
Location
MONTREAL, QC, Canada
Location
NORTH YORK, ON, Canada
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: Bicalutamide 150mg daily Other Name: Casodex™ |
Placebo Comparator: 2 | Drug: Placebo once daily |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.